Great points, GA to youThat was my thought as well. The Pivotal...

First 29 Last

Share
Profile

Follow
FreeBobby2002

863 Posts.

464

17/05/22

11:18

Post #: 61449751
Share

Originally posted by malkazoid: ↑

Well, I'm speaking from my own limited understanding of the biochemistry... but in my view the main consideration for an acquirer is going to be the timeline. Acquiring IHL-42x in July vs acquiring it in 18 months once pivotal trial results are probably in, will make a huge difference in how much they have to spend to acquire the drug candidate. The cost and added competition for acquisition probably amounts to a more significant factor than the degree to which the product actually gets de-risked by the pivotal trial in this case.

Of course it is easy for me to say this: I'm not an exec contemplating a deal for 100s of millions of dollars.
But the sum total of knowing well the two compounds in this combination drug, the strong separate safety data, and combined efficacy data, does indeed point to excellent odds for the pivotal trials. Add that we are not competing against a standard of care, and Big Pharma is going to have extremely itchy trigger fingers.

Expand

Great points, GA to you

That was my thought as well. The Pivotal trials might further de-risk the drug, but I guess the main value for BP comes due to the compressed timeline to marketing as a result of the pivotal trials, as opposed to the additional data that would be gained from it (still important).

IHL Price at posting: 48.0¢ Sentiment: Buy Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

RCE

Recce's R327 found effective against E.coli during clinical trial

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Microcap Wrap: 5 explorers with news out today

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders